Diabetes is a worldwide problem and an increasing one because of the rising numbers of obese people who are at increased risk of developing type 2 diabetes. 1 Type 2 diabetes constitute almost 90% of the diabetes. Treatment of diabetes is a substantial burden on the healthcare system because of the development of complications associated with poor control. Such complications are because of macrovascular and microvascular changes involving the heart, brain, peripheral vasculature, the kidney, eyes, and nervous system. Achieving good glycemic control reduces complications as has been ably demonstrated in studies such as the Diabetes Control and Complications Trial 2 and UK Prospective Diabetes Study (UKPDS). 3 Despite knowing that one of the principle effects of prolonged hyperglycaemia is an effect on the vasculature, little attention has been paid to the lungs, through which the entire cardiac output flows. However, logic would say that the same vascular changes that are seen elsewhere in the body should also occur in the lungs.
In this issue of the Journal, Kaparianos and colleagues summarize the evidence that suggests the lung is affected by diabetes in a manner similar to other solid organs. 4 They examine the evidence for effects on lung volumes, gas transfer across the alveolar capillary membrane, the role of autonomic neuropathy, and the potential contribution of oxidative stress. Their review raises several interesting observations.
Many studies examining lung function (forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC)) changes in diabetes have yielded conflicting results. Most were performed more than 10 years ago on small numbers of patients, in whom the duration of diabetes varied and little information on diabetic control was available. These data preceded the UKPS study, which showed the importance of glycemic control on the development of macrovascular disease (and there-fore could potentially influence pulmonary disease as well). Most were cross sectional studies which limits the usefulness of the data; large longitudinal studies such as the Copenhagen City Heart Study showed that lung volumes are slightly lower in diabetics. 5 Probably, the best information has come from the recently published clinical trials of inhaled insulin, where large numbers of wellcharacterized (non-or trivial smoker) diabetics (type 1 or type 2) were randomized to receive either inhaled insulin or subcutaneous insulin or oral agents for periods of up to 4 years. Regular standardized lung function tests were performed as part of the safety analysis. Although the focus was on the inhaled insulin group, the comparator group provided a wealth of information about changes in lung function over 6 months to 4 years treatment. Across the studies, there was a definite, small but consistent decrease in FEV1 over time (approximately 30 mL/year in type 1 diabetes; 37 mL/year in type 2 diabetes). 6, 7 The decline was stable, that is, it did not progressively worsen with time. The small change and lack of progression, together with significant pulmonary reserve, could explain why breathing difficulties are only seen in diabetics with additional cardiopulmonary stressors, such as smoking-related lung disease or congestive heart failure.
Postmortem data has confirmed that diabetes does affect the pulmonary vasculature, with advanced glycosylation end products implicated in the thickening of the alveolar capillary membrane, in addition to changes within endothelial cells and type 2 pneumocytes. 4 According to Kaparianos and colleagues, assessment of the effect of diabetes on gas transfer (diffusing capacity (DLCO)) using ventilation tests or scintigraphy gives conflicting results. 4 The substantial data from the inhaled insulin clinical trials suggest that in those subjects taking oral agents or insulin, there is an effect on DLco; however, it is small (approximately 0.2-0.3 mLs/min/mmHg loss per year). 6, 7 Kaparianos and colleagues note two interesting studies. In the first study, glucose levels were tightly controlled by use of an insulin pump and patients were more likely to have normal or near normal DLco levels. 8 In the second study, insulin given by infusion acutely (the same day) improved DLco. 9 This observation is intriguing as most evidence is for a structural change in the alveolar capillary membrane causing the reduced DLco, but the rapidity of change seen in the second study cannot be structural. The authors suggest that this could be due to improved conductance at the alveolar capillary membrane. Clearly more work is needed, but these initial observations lend support to improved glycemic control being of value for the diabetic lung.
Kaparianos and colleagues discuss two studies that suggest that previous impairment of lung function increases the risk of developing diabetes. In the Normative Aging study, pulmonary function was assessed before, at the time of diagnosis of diabetes, and on follow-up. 4 They noted that lung function decline predated the diagnosis of diabetes by many years. It should be noted, however, that most patients with type 2 diabetes (who constitute more than 90% of patients with diabetes as in the normative Aging Study) have had impaired glucose for many years before the diagnosis of type 2 diabetes is made delaying treatment by sometimes more than 10 years. It suggests that the effects of hyperglycemia on lung function occur early in the course of the disease, which would also indicate that it is at this point that efforts should be made to achieve good glycemic control.
The contribution of the autonomic nervous system to changes in pulmonary function has not been widely investigated. Kaparianos make a good argument for autonomic neuropathy being implicated in the lung function changes. There is also evidence for neuroadrenergic denervation in the diabetic lung; in one study, neuroadrenergic denervation in the lung was associated with a reduced FEV1 and FVC and increased 123I-metaiodobenzylguanidine (MIBG) clearance, an effect that interestingly was independent of diabetic control. 10 Hyperglycemia also has significant effects on skeletal muscle; in type 1 diabetes, isometric limb muscle strength and fatigue ability are worse during hyperglcemia than normoglycemia. 11 Presumably, this could also be true for the intercostals and diaphragmatic muscles.
Finally, Kaparianos and colleagues discuss the role of oxidant stress in the pulmonary effects of diabetes. Most of the work has been done in animal models of diabetes and it remains to be seen whether oxidative stress is a significant factor in the lung, independent of its effects on endothelial cells and the vasculature. Given the widespread use of ACE inhibitors for diabetic renal involvement, it will be interesting to see what effect this has on lung function if, as is hypothesised, ACE is protective against oxidative stress.
In conclusion, this review provides evidence for the involvement of the lung in diabetes and suggests an effect on both lung volumes and gas exchange and possibly oxidative stress. Although evidence is accumulating for an effect of hyperglycemia on the lung, as yet there has been little research to elucidate the underlying mechanisms. It remains to be seen whether improved glycemic control will have as much an impact on the lungs as it has had on macro-and microvascular complications elsewhere.
